Author

L. Grob

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Curioni-Fontecedro· 1 shared A. Goncalves· 1 shared A. K. Miller· 1 shared A. Kopp-Schneider· 1 shared A. Soltermann· 1 shared A. Teleman· 1 shared B. Bodenmiller· 1 shared C. Brandstaedter· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Curioni-Fontecedro

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs

J. Samarin, P. Fabrowski, R. Kurilov, H. Nuskova, J. Hummel-Eisenbeiss, H. Pink, N. Li, V. Weru, H. Alborzinia, U. Yildiz, L. Grob, M. Taubert, M. Czech, M. Morgen, C. Brandstaedter, , N. Gunkel

The paper identifies antioxidant-capacity biomarkers (ACBs) that predict susceptibility to ROS-inducing drugs in lung cancer cells, showing that low ACB expression correlates with nitric oxide levels, not ROS levels.

bioRxiv · Jan 17, 2023Cancer Biology

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and MET amplification

S. Hiltbrunner, L. Cords, S. Kasser, S. N. Freiberger, S. Kreutzer, N. C. Toussaint, L. Grob, I. Opitz, M. Messerli, M. Zoche, A. Soltermann, M. Rechsteiner, M. van den Broek, B. Bodenmiller, A. Curioni-Fontecedro

This study identifies two patterns of acquired resistance to anti-PD1 therapy in NSCLC patients, including reduced T cell infiltration and MET amplification.

bioRxiv · Apr 8, 2022 · PreprintCancer Biology